评估基于四维计算机断层扫描通气功能肺避让放疗治疗非小细胞肺癌的2期随机临床试验
这项单中心2期随机试验纳入122例接受根治性放疗的非小细胞肺癌患者,1:1随机分配至标准放疗或功能肺避让放疗。主要终点即基线至放疗后3个月4DCT通气变化在两组间无差异(1.91% vs 1.87%;P=0.90)。在常规分割队列中,功能避让组≥2级肺炎发生率更低(8.2% vs 32.3%;P=0.049),FEV1和FVC下降更少。
要点
- 功能避让计划显著降低高功能肺剂量(P<0.05),未牺牲靶区覆盖或危及器官约束。
- 全部患者中两组通气减少量无差异(1.91% vs 1.87%;P=0.90)。
- 常规分割队列功能避让组≥2级肺炎更低(8.2% vs 32.3%;P=0.049),FEV1和FVC下降更少。
核心结论
- 全部患者中两组放疗后4DCT通气变化无差异。
- 常规分割放疗联合功能肺避让的患者肺部毒性降低、肺功能检查下降更少,提示局部晚期NSCLC患者可能获益。
研究设计与样本
- 单中心、随机、2期试验,2016年至2022年入组接受根治性放疗(立体定向体部放疗或常规分割放疗)的NSCLC患者。
- 患者1:1随机分配至标准放疗或功能肺避让放疗。
- 共122例随机,116例可分析;中位随访29.9个月。
主要发现
- 功能避让计划显著降低高功能肺剂量(P<0.05),未影响靶区覆盖或危及器官约束。
- 全部患者基线至3个月通气减少量两组无差异(1.91% vs 1.87%;P=0.90)。
- 全部患者≥2级和≥3级肺部毒性分别为24.1%和8.6%,两组间肺毒性或肺功能检查变化无显著差异。
- 常规分割队列中,功能避让组≥2级肺炎发生率更低(8.2% vs 32.3%;P=0.049),3个月FEV1变化(-3 vs -5;P=0.042)和FVC变化(1.5 vs -6;P=0.005)下降更少。
关键数值与推荐
- 主要终点为基线至放疗后3个月4DCT测得的基于雅可比矩阵的通气变化。
- 次要终点包括高通气与低通气肺体积变化、肺毒性及肺功能检查变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether 4-dimensional computed tomography (4DCT) ventilation-based functional lung avoidance radiation therapy preserves pulmonary function compared with standard radiation therapy for non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This single center, randomized, phase 2 trial enrolled patients with NSCLC receiving curative intent radiation therapy with either stereotactic body radiation therapy or conventionally fractionated radiation therapy between 2016 and 2022. Patients were randomized 1:1 to standard of care radiation therapy or functional lung avoidance radiation therapy. The primary endpoint was the change in Jacobian-based ventilation as measured on 4DCT from baseline to 3 months postradiation. Secondary endpoints included changes in volume of high- and low-ventilating lung, pulmonary toxicity, and changes in pulmonary function tests (PFTs). RESULTS: A total of 122 patients were randomized and 116 were available for analysis. Median follow up was 29.9 months. Functional avoidance plans significantly (P < .05) reduced dose to high-functioning lung without compromising target coverage or organs at risk constraints. When analyzing all patients, there was no difference in the amount of lung showing a reduction in ventilation from baseline to 3 months between the 2 arms (1.91% vs 1.87%; P = .90). Overall grade ≥2 and grade ≥3 pulmonary toxicities for all patients were 24.1% and 8.6%, respectively. There was no significant difference in pulmonary toxicity or changes in PFTs between the 2 study arms. In the conventionally fractionated cohort, there was a lower rate of grade ≥2 pneumonitis (8.2% vs 32.3%; P = .049) and less of a decline in change in forced expiratory volume in 1 second (-3 vs -5; P = .042) and forced vital capacity (1.5 vs -6; P = .005) at 3 months, favoring the functional avoidance arm. CONCLUSIONS: There was no difference in posttreatment ventilation as measured by 4DCT between the arms. In the cohort of patients treated with conventionally fractionated radiation therapy with functional lung avoidance, there was reduced pulmonary toxicity, and less decline in PFTs suggesting a clinical benefit in patients with locally advanced NSCLC.
引用
- Baschnagel AM, Flakus MJ, Wallat EM, et al. A Phase 2 Randomized Clinical Trial Evaluating 4-Dimensional Computed Tomography Ventilation-Based Functional Lung Avoidance Radiation Therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387810. doi:10.1016/j.ijrobp.2024.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。